☆ 4.7 Article

Low-Dose Rivaroxaban to Prevent Recurrences of Venous Thromboembolism in Cancer: A Real-Life Experience with a Focus on Female Patients

JOURNAL OF CLINICAL MEDICINE (2023)

Related references

Note: Only part of the references are listed.

Article Cardiac & Cardiovascular Systems

Unmet clinical needs in the prevention and treatment of cancer-associated venous thromboembolism

Michela Giustozzi et al.

Summary: Venous thromboembolism (VTE), a common complication in cancer patients, has been evolving in terms of prophylaxis and treatment. The introduction of direct oral anticoagulants has significantly changed the management of cancer-associated VTE due to their ease of use and comparable efficacy and safety to low molecular weight heparins. However, the heterogeneity of cancer patients poses challenges in VTE management, including primary prophylaxis, long-term anticoagulation, and treatment in patients with high bleeding risk or specific types of VTE.

TRENDS IN CARDIOVASCULAR MEDICINE (2023)

Add to Collection

Review Hematology

Updates in the Incidence, Pathogenesis, and Management of Cancer and Venous Thromboembolism

Laura Girardi et al.

Summary: Patients with cancer have a higher risk of developing venous thromboembolism (VTE) due to specific risk factors and thrombotic and hemostatic pathophysiological pathways. Managing cancer-associated VTE can be challenging due to increased risk of recurrent events and bleeding complications. Direct oral anticoagulants have shown effectiveness, safety, and convenience compared to low-molecular-weight heparin in managing cancer-associated VTE. However, there are still unmet needs and potential solutions, such as factor XI inhibitors, to address bleeding risk, drug interactions, and liver dysfunction.

ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2023)

Add to Collection

Review Hematology

Extended anticoagulation treatment for cancer-associated thrombosis-Rates of recurrence and bleeding beyond 6 months: A systematic review

Florian Moik et al.

Summary: In this systematic review, the study provides a comprehensive summary of the best available evidence on recurrence and bleeding risk between 6 and 12 months after cancer-associated VTE. Recurrent VTE remains common beyond 6 months, with varying rates, while major bleeding rates between 6 and 12 months were relatively low. The findings support continuing anticoagulation treatment beyond 6 months in patients with active cancer.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Low dose apixaban as secondary prophylaxis of venous thromboembolism in cancer patients-30 months follow-up

Trine-Lise Larsen et al.

Summary: For cancer patients, reducing the dosage of apixaban to 2.5 mg twice daily after 6 months of full-dose treatment seems to be safe, and the incidence rate of recurrent VTE and major bleeding remains low thereafter.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Review Hematology

Anticoagulant treatment for upper extremity deep vein thrombosis: A systematic review and meta-analysis

Emanuele Valeriani et al.

Summary: This meta-analysis evaluated the efficacy and safety of anticoagulant therapy for upper extremity deep vein thrombosis (UEDVT). The results showed that anticoagulant treatment is associated with a low risk of recurrent VTE and major bleeding in patients with UEDVT.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

Extended Anticoagulant Treatment with Full- or Reduced-Dose Apixaban in Patients with Cancer-Associated Venous Thromboembolism: Rationale and Design of the API-CAT Study

Isabelle Mahe et al.

Summary: The API-CAT study aims to evaluate whether a reduced-dose regimen of apixaban is noninferior to a full-dose regimen in preventing recurrent VTE in cancer patients. This international, randomized, double-blind trial will assess VTE events as the primary efficacy outcome and clinically relevant bleeding as the principal safety endpoint.

THROMBOSIS AND HAEMOSTASIS (2022)

Add to Collection

Article Hematology

American Society of Hematology 2021 guidelines for management of venous thromboembolism: prevention and treatment in patients with cancer

Gary H. Lyman et al.

Summary: These evidence-based guidelines aim to support decision-making on the prevention and treatment of VTE in cancer patients, covering mechanical and pharmacological prophylaxis, as well as recommendations for initial, short-term, and long-term treatment based on patient risk and treatment circumstances. Recommendations vary depending on patient risk level and treatment situation.

BLOOD ADVANCES (2021)

Add to Collection

Article Hematology

OC-15 Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study

F.X. Lapébie et al.

THROMBOSIS RESEARCH (2021)

Add to Collection

Article Oncology

Are Patients with Active Cancer and Those with History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding While on Anticoagulants?

Corinne Frere et al.

CANCERS (2020)

Add to Collection

Article Medicine, General & Internal

Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer

Giancarlo Agnelli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Review Hematology

Post-thrombotic syndrome and recurrent thromboembolism in patients with upper extremity deep vein thrombosis: A systematic review and meta-analysis

Kartiga Thiyagarajah et al.

THROMBOSIS RESEARCH (2019)

Add to Collection

Article Cardiac & Cardiovascular Systems

Anticoagulation Therapy for Venous Thromboembolism in the Real World - From the COMMAND VTE Registry

Yugo Yamashita et al.

CIRCULATION JOURNAL (2018)

Add to Collection

Article Hematology

Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH

A. A. Khorana et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2018)

Add to Collection

Article Medicine, General & Internal

Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism

Gary E. Raskob et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Review Hematology

Comparisons Between Upper and Lower Extremity Deep Vein Thrombosis: A Review of the RIETE Registry

Lauren P. Cote et al.

CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS (2017)

Add to Collection

Article Medicine, General & Internal

Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

J. I. Weitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Hematology

Tinzaparin in cancer associated thrombosis beyond 6 months: TiCAT study

Luis Jara-Palomares et al.

THROMBOSIS RESEARCH (2017)

Add to Collection

Article Hematology

Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial

Gary E. Raskob et al.

LANCET HAEMATOLOGY (2016)

Add to Collection

Article Hematology

Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH

S. Kaatz et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)

Add to Collection

Article Hematology

Treatment of venous thromboembolism in cancer patients with dalteparin for up to 12months: the DALTECAN Study

C. W. Francis et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2015)

Add to Collection

Article Medicine, General & Internal

Apixaban for Extended Treatment of Venous Thromboembolism

Giancarlo Agnelli et al.

NEW ENGLAND JOURNAL OF MEDICINE (2013)

Add to Collection

Article Hematology

Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies

Martin H. Prins et al.

THROMBOSIS JOURNAL (2013)

Add to Collection

© Peeref 2019-2024. All rights reserved.